Skip to main content

Immuneering Corp 8-K, filed Oct 29, 2026

Immuneering Corp (IMRX)

8-K 2026-10-29 For: 2026-10-29
View Original
Added on October 29, 2026

About this 8-K

Immuneering Corp filed this 8-K on October 29, 2026.

Immuneering said MAPKeeper 301 enrollment is ahead of schedule, expanding the Phase 3 trial to approximately 570 patients and potentially accelerating mid-2028 topline data. Cash runway guidance was updated to the fourth quarter of 2028. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits